Akero Therapeutics(AKRO)盘前股价大涨5.82%,引起市场广泛关注。公司数据显示,盘前共涨7.05美元,报127.05美元。
这一涨势或与多家分析师机构近期上调对其目标股价预期有关。据悉,Canaccord Genuity将其目标价从56美元上调至73美元,H.C. Wainwright也从50美元上调至72美元。此外,摩根大通将目标价从49美元上调至73美元,看好该公司未来前景。
分析师为何如此看好Akero?具体原因暂时无从得知,但市场显然对这一药企发展前景抱有信心。不过该股尚处于盘前交易阶段,后市表现如何仍有待关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.